Micro-implant d’acétonide de fluocinolone (ILUVIEN®) pour l’œdème maculaire diabétique chronique
| Autor: | Francine Behar-Cohen, G. Soubrane |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
medicine.medical_specialty
genetic structures biology business.industry Acétonide de fluocinolone VEGF receptors Diabetic macular edema Treatment options Foveal thickness Long term results Diabetic retinopathy medicine.disease eye diseases Surgery Ophthalmology Fluocinolone acetonide medicine biology.protein business medicine.drug |
| Zdroj: | Journal Français d'Ophtalmologie. 38:159-167 |
| ISSN: | 0181-5512 |
| DOI: | 10.1016/j.jfo.2014.09.007 |
| Popis: | Diabetic macular edema (DME) is a frequent complication of diabetic retinopathy and may cause severe visual loss. In this article, we examine the pathophysiology of DME and review various treatment options, such as laser photocoagulation, anti-vascular endothelial growth factor (VEGF) receptor antibodies, and steroids including ILUVIEN(®), which is a new sustained-release, non biodegradable, injectable, intravitreal micro-implant containing fluocinolone acetonide. The results of the FAME (Fluocinolone Acetonide in Diabetic Macular Edema) studies, conducted to evaluate the efficacy and safety of ILUVIEN(®) in DME, are discussed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|